3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Other hematologic neoplasm
1
Conditions
Leukemia, Myeloid, Acute
2
Solid Tumors
1
Recurrence
1
Myelodysplastic Syndromes
1
Metastatic Solid Tumors
1
Leukemia, Myelomonocytic, Chronic
1
Advanced Malignant Neoplasm
1
Interventions
Dexamethasone
33
Cyclophosphamide
29
venetoclax
18
fludarabine
18
Lenalidomide
16
Bortezomib
16
Cytarabine
13
pembrolizumab
12
Calcium Dobesilate
12
Carboplatin
11
fludarabine phosphate
10
Rituximab
10
pomalidomide
9
Gemcitabine
9
Nivolumab
8
Azacitidine
7
daratumumab
6
carfilzomib
6
blinatumomab
6
Decitabine
6
Bendamustine Hydrochloride
6
selinexor
5
obinutuzumab
5
ibrutinib
5
Vincristine
5
Temozolomide
5
Methotrexate
5
Etoposide
5
Cisplatin
5
tafasitamab
4
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 1/2
×
Recurrence
×
Infusions, Intravenous
×
Clear all
NCT03850574
2025-08-26
TUSCANY
Aptose Biosciences Inc.
Phase 1/2
Recruiting
240 enrolled